 |
|
 |
Company Information |
|
|
Pfizer Global and US Analysis
PharmaVitae 2005
Publication Date October 2005
Publisher Datamonitor
Product Type Report
Pages 215
ISBN Number not applicable
Product Code DAT404
|
|
|
Summary
This analysis examines the current position and future outlook for Pfizer in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
- Benchmark Pfizer's performance against key rivals in the ethical pharmaceutical sector
- Understand the impact of the withdrawal of Bextra on Pfizer's future sales growth
- Evaluate the impact of forthcoming patent expiries
|
Content
- Chapter 1 Executive Summary
- Key findings
- Current positioning: competitive outlook 2004
- Future performance: growth drivers and resistors 2005-10
- Evolution in therapeutic focus: 2005-10
- Strong performers
- Underperformers
- Key issues facing Pfizer: 2005-10
- Two key challenges
- Strategic outlook
- Chapter 2 Global Company Strategy
- Introduction to Pfizer
- Assessment of strategic position
- Strengths
- Weaknesses
- Opportunities
- Threats
- Therapeutic strategies
- Pipeline development strategies
- Growth strategies
- A keen big merger player to increase critical mass
- The key components of Pfizer's corporate development
- Divesting low-margin units to boost profitability
- Increasing investment in acquiring innovative platforms
- Focusing on attractive licensing deals to speed up pipeline growth
- Geographical expansion
- Chapter 3 Global Portfolio And Pipeline Analysis
- Therapy area focus in 2004
- Forecast revenue stream, 2004-10
- Therapy area forecasts to 2010
- Growth drivers, 2003-04
- Growth drivers, 2005-10
- Cardiovascular franchise
- Marketed products
- R&D compounds
- Cardiovascular portfolio sales forecasts and forecast revenue growth
- CNS franchise
- Marketed products
- R&D compounds
- CNS portfolio sales forecasts and forecast revenue growth
- Arthritis, immune and inflammatory disorders (AIID) franchise
- Marketed products
- R&D compounds
- AIID portfolio sales forecasts
- Infectious disease franchise
- Marketed products
- R&D compounds
- Infectious disease portfolio sales forecasts
- Urology franchise
- Marketed products
- R&D compounds
- Urology portfolio sales forecasts
- Oncology franchise
- Marketed products
- R&D compounds
- Oncology portfolio sales forecasts
- Diabetes and endocrinology franchise
- Marketed products
- R&D compounds
- Diabetes & endocrinology portfolio sales forecasts
- 'Other' products
- Marketed products
- R&D compounds
- 'Other' products sales forecasts
- Chapter 4 Us Strategy, Portfolio And Pipeline
- US therapy area focus in 2004
- Forecast US revenue stream, 2005-10
- Cardiovascular portfolio US sales forecasts
- CNS portfolio US sales forecasts and forecast revenue growth
- AIID portfolio US sales forecasts
- Infectious disease portfolio US sales forecasts
- Urology portfolio US sales forecasts
- Oncology portfolio US sales forecasts
- Diabetes and endocrinology portfolio US sales forecasts
- 'Others' portfolio US sales forecasts
- Chapter 5 Corporate Development
- Financial position, 2000-04
- Profitability, 2000-04
- Revenue growth
- Cost structure
- Liquidity, 2000-04
- 2004 performance benchmarking
- Business model clustering according to 2004 cost ratios
- Key events shaping corporate activity, 2000-05
- Merger and acquisition activity
- Corporate alliances and deals
- Other business development and news
- Chapter 6 Appendix: Supporting Data
- Financial data
- Exchange rates
- Methodology for therapy area forecasting
- List Of Tables
- Table 1: Geographic split of Pfizer's corporate revenues, 2003-04
- Table 2: Breakdown of Pfizer's ethical sales by therapy area, 2003-04
- Table 3: Forecast sales for Pfizer's major therapy areas, 2005-10
- Table 4: Sales of Pfizer's top-selling drugs, 2003-04
- Table 5: Forecast sales for Pfizer's top-selling drugs, 2005-10
- Table 6: Pfizer's marketed cardiovascular portfolio
- Table 7: Pfizer's cardiovascular R&D pipeline, 2005
- Table 8: Forecast sales for Pfizer's cardiovascular portfolio, 2005-10
- Table 9: Pfizer's marketed CNS portfolio
- Table 10: Pfizer's CNS R&D pipeline, 2005
- Table 11: Forecast sales for Pfizer's CNS portfolio, 2005-10
- Table 12: Pfizer's marketed AIID portfolio
- Table 13: Forecast sales for Pfizer's AIID portfolio, 2005-10
- Table 14: Pfizer's marketed infectious disease portfolio
- Table 15: Pfizer's infectious disease R&D pipeline, 2005
- Table 16: Forecast sales for Pfizer's infectious disease portfolio, 2005-10
- Table 17: Pfizer's marketed urology portfolio
- Table 18: Forecast sales for Pfizer's urology portfolio, 2005-10
- Table 19: Pfizer's marketed oncology portfolio
- Table 20: Pfizer's oncology R&D pipeline, 2005
- Table 21: Forecast sales for Pfizer's oncology portfolio, 2005-10
- Table 22: Pfizer's marketed diabetes & endocrinology portfolio
- Table 23: Pfizer's diabetes & endocrinology R&D pipeline, 2005
- Table 24: Forecast sales for Pfizer's diabetes & endocrinology portfolio, 2005-10
- Table 25: Pfizer's 'other' marketed products
- Table 26: Pfizer's 'Other' R&D products, 2005
- Table 27: Forecast sales of Pfizer's 'others' products portfolio, 2005-10
- Table 28: Breakdown of Pfizer's US ethical sales by therapy area, 2003-04
- Table 29: Forecast US sales for Pfizer's major therapy areas, 2004-10
- Table 30: Forecast US sales for Pfizer's cardiovascular portfolio, 2005-10
- Table 31: Forecast US sales for Pfizer's CNS portfolio, 2005-10
- Table 32: Forecast US sales for Pfizer's AIID portfolio, 2005-10
- Table 33: Forecast US sales for Pfizer's infectious disease portfolio, 2005-10
- Table 34: Forecast US sales for Pfizer's urology portfolio, 2005-10
- Table 35: Forecast US sales for Pfizer's oncology portfolio, 2005-10
- Table 36: Forecast US sales for Pfizer's diabetes and endocrinology portfolio, 2005-10
- Table 37: Forecast US sales for Pfizer's 'others' portfolio, 2005-10
- Table 38: Pfizer's revenues by division, 2003-04
- Table 39: Pfizer's operating expenses and operating profit, 2003-04
- Table 40: Summary of Pfizer's historical M&A and divesting activities, 2000-05
- Table 41: Summary of Pfizer's historical agreements, 2003-04
- Table 42: Exchange rates*, 2005
- List Of Figures
- Figure 1: Competitive positioning of Pfizer within the leading pharmaceutical sector, 2004
- Figure 2: Pfizer's growth drivers and resistors, 2005-10
- Figure 3: Evolution of Pfizer's therapeutic focus, 2005-10
- Figure 4: Key issues that Pfizer is expected to face between 2005 and 2010
- Figure 5: Assessment of Pfizer's strategic position, 2005
- Figure 6: Breakdown of Pfizer's corporate revenues in 2003 and 2004
- Figure 7: Patent expiries or product withdrawals will erode sales of numerous Pfizer's leading products
- Figure 8: Development of Pfizer's therapeutic strategy, 2004-10
- Figure 9: The structure of Pfizer's current early- and late-stage clinical pipeline, according to phase of development in 2005
- Figure 10: Therapeutic focus for Pfizer's current early- and late-stage clinical pipeline, 2005
- Figure 11: Breakdown of Pfizer's pipeline-driven sales, 2005-10
- Figure 12: The key elements of Pfizer's organic growth strategies
- Figure 13: Breakdown of Pfizer's sales by region, 2002-04
- Figure 14: Breakdown of Pfizer's ethical sales by therapy area, 2004
- Figure 15: Forecast sales for Pfizer's major therapy areas, 2005-10
- Figure 16: Contribution of Pfizer's top-selling drugs to ethical sales in 2004
- Figure 17: Breakdown of cardiovascular sales by drug, 2004
- Figure 18: Study results of Lipitor vs. Lipitor torcetrapib combination
- Figure 19: Forecast sales for Pfizer's cardiovascular franchise, 2005-10
- Figure 20: Breakdown of CNS sales by drug in 2002 and 2004
- Figure 21: Forecast sales for Pfizer's CNS franchise, 2005-10
- Figure 22: Breakdown of AIID sales by drug in 2002 and 2004
- Figure 23: Forecast sales for Pfizer's AIID franchise, 2005-10
- Figure 24: Forecast sales for Pfizer's infectious disease franchise, 2005-10
- Figure 25: Forecast sales for Pfizer's urology franchise, 2005-10
- Figure 26: Forecast sales for Pfizer's oncology franchise, 2005-10
- Figure 27: Forecast sales for Pfizer's diabetes & endocrinology franchise, 2005-10
- Figure 28: Pfizer's profitability stream, 2000-04
- Figure 29: Pfizer's liquid assets versus total liabilities, 2000-04
- Figure 30: R&D and S,G&A spend and COGS as a proportion of revenue, 2004
|
|
|
